Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Isoginkgetin reduces inflammation in cells by blocking NF-κB activation.

This study found that the newly developed microarray patches for intradermal delivery of finasteride showed high drug content and significantly improved skin deposition compared to existing methods.

This case report highlights that frontal fibrosing alopecia may be underrecognized in young women and notes that no single treatment regimen has been proven consistently effective for this condition.

This issue information abstract introduces a collection of articles, including one on hair keratins' unique filament formation, without reporting new experimental findings itself.

In this in vitro study, Yifa Compound Prescription was reported to enhance human hair follicle growth and increase VEGF mRNA expression compared to blank serum.

This study reports that a multifunctional artificial skin using photothermal-triggered drug delivery improved full-thickness wound healing and skin appendage regeneration by coordinating the release of several therapeutic agents.

This study found that Forsythiaside A may protect against sepsis-induced acute kidney injury in mice by reducing inflammation and apoptosis through modulation of ER stress responses.

In in-vitro experiments, this study found that poncirin showed higher inhibitory activity against JAK3 than tofacitinib, suggesting potential for alopecia areata treatment.

This study concluded that the Free Androgen Index (FAI) could serve as a reliable biomarker for hyperandrogenism in women with androgenetic alopecia, showing more predictive value than testosterone or SHBG alone.

This study of fifty female patients with frontal fibrosing alopecia in Egypt found that it is a complex condition with no definitive treatment, as it often co-occurs with lichen planus and thyroid issues.

This review discusses the etiology, pathogenesis, clinical presentation, and treatment of frontal fibrosing alopecia, noting the lack of clinical trial data and limited observational treatment results.

Sfrp2 increases during hair follicle catagen phase and slows keratinocyte growth.

This study demonstrated that PGF 2α significantly stimulates hair growth in human hair follicles via a receptor-driven mechanism, with a notably stronger response in intermediate follicles than in terminal ones, suggesting potential clinical significance for conditions like alopecia.

The researchers reported that individuals with non-alcoholic fatty liver disease and nutritional deficiency often exhibit iron and estrogen deficiencies, which may contribute to liver cell stress and fibrosis.

This study reports that anifrolumab showed promising improvement in a case of refractory discoid lupus erythematosus, specifically enhancing skin lesions and promoting hair regrowth, suggesting potential as an effective therapy for severe cases.

This study found that Cnidium officinale extract and its compound ferulic acid improved hair growth by promoting dermal papilla cell function and mitochondrial activity, suggesting their potential as a new treatment option for alopecia, possibly through estrogen receptor alpha activation.

In this study, researchers synthesized nine new nicotinamide derivative compounds and found that one, identified as N4, exhibited significant cytotoxic effects on MCF-7 breast cancer cells, while other derivatives demonstrated notable antibacterial, antifungal, and antibiofilm activities.

This review discusses the potential usefulness and safety profile of oral antiandrogens for treating frontal fibrosing alopecia, noting possible benefits but acknowledges that finasteride's efficacy remains uncertain.

Nelfb is essential for dermal fat development and survival.

This study found that the trichogenicity of cultured human outer root sheath follicular keratinocytes decreased with longer cultivation periods and was significantly influenced by the expression of the transcription factor FOXA2.

This letter discusses findings from an article by Sun et al. showing that neodymium doped yttrium aluminum garnet laser effectively treats prominent facial vasculature in patients with frontal fibrosing alopecia, but highlights concerns about the risk of iatrogenic scarring and suggests caution with treatment frequency.

This case report details the first known instance of interferon-induced lichen planus in a seronegative HCV patient with metastatic renal cell carcinoma.

This study found that a novel nano-engineered platform, PCA, significantly promoted hair regeneration in an androgenetic alopecia mouse model by enhancing angiogenesis and hair follicle stem cell proliferation, showing promise for future hair regrowth treatments.

This study of alopecia areata patients found that a 10 mg twice-daily dose of oral tofacitinib led to significant hair regrowth, suggesting it may be beneficial for treatment.

This study suggests that specific combinations of human type I and II hair keratins, particularly K35-K85 and K36-K81, have distinct in vitro assembly properties that are significant for macrofibril formation.

This study found that sterile fucoidan promotes T cell proliferation but reduces differentiation at higher concentrations and suppresses osteogenic differentiation in co-cultured environments.

In this study, FOL-026, a peptide based on osteopontin, was shown to promote angiogenesis and stimulate vascular cell proliferation and migration through neuropilin-1, similar to VEGF, suggesting potential therapeutic applications in vascular repair and angiogenesis-related conditions.

TNF-a may not be as involved in certain types of hair loss as previously thought.

This study found that oral tofacitinib monotherapy improved nail changes in 73.3% of adults with moderate-to-severe alopecia areata over a median period of 5 months, but nail improvement was not linked to the severity of hair loss or hair regrowth.

In this study, gelatin-coated transferosomes were developed to deliver tofacitinib specifically to hair follicles, resulting in 80% hair regrowth in alopecia areata patients with recalcitrant lesions after 12 weeks of treatment.